A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma

NCT07432022 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

115

Enrollment

INDUSTRY

Sponsor class

Conditions

Combination Therapy
Aggressive B-Cell Non-Hodgkin Lymphoma
EMB07
phaseI/II

Interventions

DRUG: EMB07
DRUG: Rituximab/Gemcitabine/Oxaliplatin

Sponsor

Shanghai EpimAb Biotherapeutics Co., Ltd.